Amy J Lilly1, Meredith Johnson2, Cherie M Kuzmiak3, David W Ollila4, Siobhan M O'Connor1, Johann D Hertel1, Benjamin C Calhoun5. 1. Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA. 2. Department of Radiology, University of North Carolina, Chapel Hill, NC, USA. 3. Department of Radiology, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. 4. Department of Surgery, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. 5. Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: ben.calhoun@unchealth.unc.edu.
Abstract
OBJECTIVE: Breast MRI is used to screen high-risk patients and determine extent of disease in breast cancer (BC) patients. The goal of this study was to determine the pathologic correlates of breast MRI abnormalities biopsied under MRI guidance. METHODS: We retrospectively identified 101 MRI-guided core needle biopsies (CNB) of the breast from 79 women over a 4-year period. MRI-detected lesions biopsied with ultrasound or stereotactic guidance were excluded. MRI studies and pathology were reviewed by breast radiologists and pathologists. RESULTS: Of the 79 patients, 72 (91%) had a history of prior (n = 13) or concurrent (n = 59) BC. There were 101 MRI abnormalities: 60 (59%) with non-mass enhancement (NME) and 41 (41%) with mass enhancement. Pathology was benign in 83/101 (82%), including in the majority of NME lesions (43/60, 72%). The most common benign findings were: fibrocystic changes (FCC) (49%), sclerosing lesions (13%), and fibroadenoma (FA) (9%). There were 18 (18%) malignant diagnoses: 8 (44%) invasive lobular carcinoma (ILC), 7 (39%) ductal carcinoma in situ (DCIS), and 3 (17%) invasive ductal carcinoma (IDC). Of the 18 malignant diagnoses, 16 (89%) occurred in 14 unique patients with concurrent BC. Based on the malignant MRI-guided CNB, 6 (46%) of these patients had additional (sentinel lymph node biopsy or contralateral breast surgery) or more extensive (wider lumpectomy) surgery. CONCLUSION: In this series, most MRI-guided CNB of the breast were benign. The vast majority of malignant diagnoses occurred in patients with concurrent BC and frequently resulted in changes in clinical management.
OBJECTIVE: Breast MRI is used to screen high-risk patients and determine extent of disease in breast cancer (BC) patients. The goal of this study was to determine the pathologic correlates of breast MRI abnormalities biopsied under MRI guidance. METHODS: We retrospectively identified 101 MRI-guided core needle biopsies (CNB) of the breast from 79 women over a 4-year period. MRI-detected lesions biopsied with ultrasound or stereotactic guidance were excluded. MRI studies and pathology were reviewed by breast radiologists and pathologists. RESULTS: Of the 79 patients, 72 (91%) had a history of prior (n = 13) or concurrent (n = 59) BC. There were 101 MRI abnormalities: 60 (59%) with non-mass enhancement (NME) and 41 (41%) with mass enhancement. Pathology was benign in 83/101 (82%), including in the majority of NME lesions (43/60, 72%). The most common benign findings were: fibrocystic changes (FCC) (49%), sclerosing lesions (13%), and fibroadenoma (FA) (9%). There were 18 (18%) malignant diagnoses: 8 (44%) invasive lobular carcinoma (ILC), 7 (39%) ductal carcinoma in situ (DCIS), and 3 (17%) invasive ductal carcinoma (IDC). Of the 18 malignant diagnoses, 16 (89%) occurred in 14 unique patients with concurrent BC. Based on the malignant MRI-guided CNB, 6 (46%) of these patients had additional (sentinel lymph node biopsy or contralateral breast surgery) or more extensive (wider lumpectomy) surgery. CONCLUSION: In this series, most MRI-guided CNB of the breast were benign. The vast majority of malignant diagnoses occurred in patients with concurrent BC and frequently resulted in changes in clinical management.
Authors: Nicky H G M Peters; Inne H M Borel Rinkes; Nicolaas P A Zuithoff; Willem P T M Mali; Karel G M Moons; Petra H M Peeters Journal: Radiology Date: 2007-11-16 Impact factor: 11.105
Authors: Debbie Saslow; Carla Boetes; Wylie Burke; Steven Harms; Martin O Leach; Constance D Lehman; Elizabeth Morris; Etta Pisano; Mitchell Schnall; Stephen Sener; Robert A Smith; Ellen Warner; Martin Yaffe; Kimberly S Andrews; Christy A Russell Journal: CA Cancer J Clin Date: 2007 Mar-Apr Impact factor: 508.702
Authors: Therese B Bevers; Benjamin O Anderson; Ermelinda Bonaccio; Saundra Buys; Sandra Buys; Mary B Daly; Peter J Dempsey; William B Farrar; Irving Fleming; Judy E Garber; Randall E Harris; Alexandra S Heerdt; Mark Helvie; John G Huff; Nazanin Khakpour; Seema A Khan; Helen Krontiras; Gary Lyman; Elizabeth Rafferty; Sara Shaw; Mary Lou Smith; Theodore N Tsangaris; Cheryl Williams; Thomas Yankeelov; Thomas Yaneeklov Journal: J Natl Compr Canc Netw Date: 2009-11 Impact factor: 11.908
Authors: Diana S M Buist; Linn Abraham; Christoph I Lee; Janie M Lee; Constance Lehman; Ellen S O'Meara; Natasha K Stout; Louise M Henderson; Deirdre Hill; Karen J Wernli; Jennifer S Haas; Anna N A Tosteson; Karla Kerlikowske; Tracy Onega Journal: JAMA Intern Med Date: 2018-04-01 Impact factor: 21.873
Authors: Claudia Perlet; Sylvia H Heywang-Kobrunner; Anke Heinig; Harald Sittek; Jan Casselman; Ingvar Anderson; Patrick Taourel Journal: Cancer Date: 2006-03-01 Impact factor: 6.860
Authors: Debra L Monticciolo; Mary S Newell; Linda Moy; Bethany Niell; Barbara Monsees; Edward A Sickles Journal: J Am Coll Radiol Date: 2018-01-19 Impact factor: 5.532